Cargando…
So Much to Say on the Best of What's Around Regarding Sodium‐Glucose Cotransporter‐2 Inhibitors in Acute Myocardial Infarction
Autores principales: | Nunes, Jairo T., Udell, Jacob A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382119/ https://www.ncbi.nlm.nih.gov/pubmed/37421265 http://dx.doi.org/10.1161/JAHA.123.030495 |
Ejemplares similares
-
“Breast is best”… until they say so
por: Quinones, Cristina
Publicado: (2023) -
Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
por: Gilbert, Richard E., et al.
Publicado: (2019) -
In Reply to “Letter Regarding ‘Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis’”
por: Anan, Go, et al.
Publicado: (2023) -
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
por: Severino, Paolo, et al.
Publicado: (2021) -
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)
por: Udell, Jacob A., et al.
Publicado: (2018)